GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Drugs Ltd (BOM:524348) » Definitions » Return-on-Tangible-Asset

Aarti Drugs (BOM:524348) Return-on-Tangible-Asset : 7.90% (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Aarti Drugs Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Aarti Drugs's annualized Net Income for the quarter that ended in Mar. 2024 was ₹1,892 Mil. Aarti Drugs's average total tangible assets for the quarter that ended in Mar. 2024 was ₹23,955 Mil. Therefore, Aarti Drugs's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 7.90%.

The historical rank and industry rank for Aarti Drugs's Return-on-Tangible-Asset or its related term are showing as below:

BOM:524348' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.33   Med: 7.16   Max: 16.79
Current: 7.18

During the past 13 years, Aarti Drugs's highest Return-on-Tangible-Asset was 16.79%. The lowest was 6.33%. And the median was 7.16%.

BOM:524348's Return-on-Tangible-Asset is ranked better than
72.8% of 1081 companies
in the Drug Manufacturers industry
Industry Median: 1.83 vs BOM:524348: 7.18

Aarti Drugs Return-on-Tangible-Asset Historical Data

The historical data trend for Aarti Drugs's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Drugs Return-on-Tangible-Asset Chart

Aarti Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.34 16.79 10.32 7.19 7.12

Aarti Drugs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.27 7.91 6.74 6.24 7.90

Competitive Comparison of Aarti Drugs's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Drugs's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's Return-on-Tangible-Asset falls into.



Aarti Drugs Return-on-Tangible-Asset Calculation

Aarti Drugs's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=1714.2/( (24206.09+23955.3)/ 2 )
=1714.2/24080.695
=7.12 %

Aarti Drugs's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=1892.4/( (0+23955.3)/ 1 )
=1892.4/23955.3
=7.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Aarti Drugs  (BOM:524348) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Aarti Drugs Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Aarti Drugs's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarti Drugs (BOM:524348) Business Description

Traded in Other Exchanges
Address
Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400 022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm generates the majority of its revenue from India.

Aarti Drugs (BOM:524348) Headlines

No Headlines